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Summary
Ductal carcinoma in situ is a non-invasive form of breast cancer. Its incidence is increasing due to 
widespread use of mammographic screening. It presents several diagnostic and management 
challenges in part due to its relatively indolent behaviour. Most series analysing biomarkers in 
these lesions are small (<100 patients) and large clinical trials have not been frequent. Herein, we 
review the recent progress made in understanding the biology of this entity and the tools available 
for prognostication.
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INTRODUCTION
The biological basis of micro-calcifications within the breast is poorly defined. In spite of 
this, it is common to observe micro-calcifications in benign ducts as well as in pre-invasive 
lesions of the breast. It has long been recognised that breast cancer can be associated with 
micro-calcifications. Although mammography also detects architectural distortion and 
masses, the science of mammography is based on the detection of presence and pattern of 
calcifications. As in situ lesions tend to exhibit micro-calcifications more frequently than 
invasive carcinoma, it is natural that the incidence of detecting pre-invasive lesions has 
dramatically increased (up to 20%) following the routine use of mammographic screening.1
In the pre-mammographic era, ductal carcinoma in situ (DCIS) was a palpable lesion 
accounting for approximately 1–2% of cases.2 It is believed that palpable DCIS may be 
biologically different from screen detected DCIS. Although peri-ductal fibrosis is frequently 
observed in DCIS, its aetiology is far from clear. One possible explanation is that it 
represents a reaction to ‘early’ invasion either in the form of cells or cellular products which 
might play a critical role in this process. Pathologists should regard this lesion with caution 
and generous sampling of the tissues to identify small foci of invasion is prudent. On the 
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clinical side, particularly in the United States, many surgeons prefer to perform a priori 
sentinel node biopsies for these lesions. From the biological aspect, these lesions are of great 
interest for the study of tumour microenvironment and the changes associated with the 
process of invasion.
There has been significant progress in the last few years in our understanding of DCIS and 
its management. The focus of this review is to highlight some of these aspects while 
underlining the large number of unknowns and the need to devise better methods for 
studying this entity. We presume that the readers of this review are conversant with the 
basics of DCIS and these issues will not be reviewed in detail.
DIAGNOSTIC CRITERIA
The morphological changes in DCIS lie within in the spectrum of hyperplasia and invasive 
cancer. The criteria for differentiation of DCIS from hyperplastic lesions are well described. 
Stains for high molecular weight keratins (HMWK) can be used to assist the distinction of 
DCIS from usual hyperplasia. The distinction of DCIS from atypical ductal hyperplasia 
(ADH) is based on examination of architectural, cytological and nuclear features. Size of the 
lesion is also an important consideration, with diagnosis of ADH being favoured for smaller 
lesions. Immunohistochemistry has little role to play in the distinction of DCIS from ADH. 
However, the strong and uniform expression of oestrogen receptor (ER), indicative of clonal 
proliferation, can been used to support the diagnosis of DCIS in difficult cases. Stains for 
basal and myoepithelial markers aid in the identification of invasion. However, some forms 
of non-invasive lesions such solid papillary carcinoma might not retain myoepithelial 
staining.
TERMINOLOGY FOR DCIS
Long-term follow-up studies have documented high overall survival rates (>95% at 10 years) 
for DCIS; this includes death due to any cause such as road traffic accidents and 
cardiovascular events. This has raised the important issue of whether DCIS be considered 
‘cancer’? The term ‘cancer’ is associated with considerable emotional baggage including the 
fear of chemotherapy, and death. The logic of applying such a charged word to something 
that is indolent and very unlikely to cause significant impediment to life has been 
questioned. This is particularly true for lobular carcinoma in situ (LCIS), which undergoes 
spontaneous regression in the vast majority of cases. Although it has been suggested that the 
term carcinoma should be avoided,3 there is poor consensus on the replacement terminology. 
The term ‘indolent lesions of epithelial origin (IDLE)’4 has been suggested but is not yet 
widely adopted. There are concerns that the term ‘indolent’ might not convey the marked 
increase in risk for the development of invasive carcinoma and might result in 
undertreatment of patients.
ASSESSING THE BIOLOGY OF DCIS
The wide variations in series size and the treatments offered has added to the confusion 
regarding the prognostic factors in DCIS. Most series of DCIS are small (100–200 patients), 
Badve and Gökmen-Polar Page 2













limited by follow-up data and have variable endpoints for outcome assessment, i.e., 
recurrence of DCIS or development of invasive carcinoma or both. Despite this a few 
generalisations can be made and these are discussed below.
Clinical and histopathological features
Younger age is associated with increased risk of recurrence of DCIS. This has been observed 
in almost all the series and clinical trials. The size of DCIS is also a poor prognostic factor 
with larger size being associated with greater risk of recurrence. The measurement of size of 
DCIS is not always easy and multiple methods for measurement have been described (for 
review see Lester et al.5). Accurate assessment of size is greatly aided by a good 
mammographic correlation.
Margin status is another important consideration. A number of different definitions have 
been used to define ‘clear’ margins. The NSABP trials have used absence of ‘ink-on-
tumour’ for margin negativity, whereas other groups have used 1 mm, 3 mm, 5 mm and even 
1 cm margins. The precise definition was quite arbitrary until the recent Society of Surgical 
Oncology-American Society for Radiation Oncology-American Society of Clinical 
Oncology (SSO-ASTRO-ASCO) DCIS consensus on margin status.6 These guidelines 
recommend adoption of greater than 2 mm as definition of clear margins, and use of clinical 
judgement for re-excision of lesions with 0–2 mm margin status; these have been 
successfully implemented within the surgical community.7
Architectural features are used to classify DCIS into comedo, solid, cribriform, 
micropapillary and other subtypes.8 Comedo DCIS has been associated with earlier 
recurrences and micropapillary pattern with extensive/large disease volume. A number of 
systems have been used to determine histological grade of DCIS.8 Some of these evaluate 
cellular features as well as cell polarity, while others are based entirely on nuclear grade. 
The role of grade in determination of likelihood of recurrence has been controversial. In the 
subset of patients (n=327) from the E5194 clinical trial that was used to develop/validate the 
DCIS Score (Genomic Health, USA), grade [College of American Pathologists (CAP) 
grading system] and histological features were not associated with recurrence.9 In contrast, 
in the parent trial (n=665), high grade was predictive of outcome at 10 and 12 years.10 The 
importance of grade was also confirmed in analysis of 57,222 DCIS cases from the SEER 
database by Sagara et al.11 The weighted 10-year breast cancer-specific survival hazard 
ratios of low grade DCIS cases were significantly different for intermediate and high grade 
DCIS [low grade hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.21–3.52; 
intermediate grade HR 0.23, 95% CI 0.14–0.42; and high grade HR 0.15, 95% CI 0.11–
0.23].11
Stromal features have also been used for prognostication. The presence of periductal fibrosis 
has been associated with increased likelihood of recurrence.12 The mechanisms associated 
with the development of this feature is uncertain. Some studies have implicated cancer 
associated fibroblasts (CAFs) as the basis for the altered stroma and for making the tumour 
microenvironment more conducive for the development of invasive cancer.13,14 Periductal 
angiogenesis is also often seen in DCIS; the significance of this feature is uncertain. The 
Badve and Gökmen-Polar Page 3













failure of anti-angiogenic therapies in the treatment of invasive breast cancer has led to a 
diminishing interest in understanding the molecular basis of this feature.15
The recognition importance of stromal tumour infiltrating lymphocytes (TILs) in breast 
cancer, particularly triple negative breast cancer,16–18 has led to a number of studies 
investigating immune cells in DCIS. DCIS cases harbour stromal TILs, where they are 
associated with younger age, symptomatic presentation, larger size, higher nuclear grade, 
comedo necrosis and ER negativity as well as shorter recurrence-free interval.19 Similarly, 
high grade DCIS cases are also likely to show expression of FOXP3, CD68, CD4, CD20, 
HLA-DR20 and PD-L1.21 Further parsing of the data is necessary to identify the exact role 
of TILs in DCIS. The association of immune cells with poor prognosis DCIS could be 
indicative of a breach of the integrity of the basement membrane, at least at a molecular 
level. Figure 1 shows infiltration by immune cells in ductal carcinoma in situ (DCIS).
Biological parameters
Protein analysis—Immunohistochemistry has been extensively used to identify 
prognostic factors in DCIS; however, most studies are limited by small sample size and 
limited follow-up. In spite of this, there are several important parameters that can be used for 
prognostication. A number of markers related to proliferation, cell cycle regulation, 
apoptosis, angiogenesis, extracellular matrix proteins (CD10, SPARC) and inflammation 
including COX2 have been analysed in DCIS. A detailed meta-analysis of the biological 
markers and risk of recurrence was performed by Lari and Kuerer22 in 2011; much of the 
data stands to date and will not be reproduced herein but salient features will be highlighted.
Expression of ER is observed in greater than 80% of cases and in some series 90–95% of 
cases (E5194 and Toronto cohorts23–26) while progesterone receptor (PR) expression is 
observed in approximately 60% of cases.22 ER negative DCIS has been associated with 
increased likelihood of recurrence. The analysis of expression of ER and PR has become 
commonplace in the management of DCIS. This in part due to the data from the NSABP 
B-24 study, which assessed the benefit of tamoxifen in 732 patients treated with surgery and 
radiation.27 The patients with ER+ DCIS (76%) had significant benefit from tamoxifen (HR 
0.64) at 10 years of follow-up. However, the 22 patients with ER negative DCIS did not 
obtain any benefit. Although this data has not been further validated, it was deemed practice 
changing with resultant implementation in clinical practice.
The expression of HER2 has been analysed in a number of cohorts reviewed by Sanati.26 
Expression has been associated with increased likelihood of development of recurrence. Of 
interest, expression of HER2 is observed in around 40% of cases of DCIS which is a 
significantly higher rate than in invasive cancer. Theories to explain this finding include loss 
of HER2 during progression, invasion arising from a distinct clone with HER2 positive cells 
acting as ‘enablers’ during the process.
The expression of Ki-67 has been analysed in a number of series. The expression in DCIS, 
in contrast to invasive cancer, tends to be low. In most series, this results in poor correlation 
with outcomes. In a large series of patients, Kerlikowske et al. demonstrated that the 
combination of Ki-67 with COX2 and p16 expression could predict development of 
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recurrence.28 More recently, this set of markers has been expanded to include HER2, PR, 
Ki-67, COX2, p16/INK4A, FOXA1 and SIAH2 and available as a commercial assay 
DCISionRT from PreludeDx (discussed later).29,30
We have analysed the co-expression of multiple proteins in DCIS using multiplex 
immunofluorescence on a single 5 μm section. The study revealed marked heterogeneity in 
expression of oncologically relevant proteins in cells located within the same duct.31 In 
addition, there was variability in degree of heterogeneity with some ducts containing 
predominantly a single subtype of cells while others showing the presence of multiple 
subpopulations. Further analyses seeking to understand the biological meaning of these 
findings are ongoing. Figure 2 shows heterogeneity in the morphological patterns of DCIS.
Genomic analysis—Copy number analysis has been used to study the biology of DCIS 
(reviewed by Rane et al.32). Array comparative genomic hybridisation (aCGH) analysis has 
confirmed the presence of low and high grade pathways in DCIS. The low grade pathway is 
associated with loss of 16q and variable gain of 1q. Deletions of 16q are rare in the high 
grade pathway, while alterations of 8p, 11q, 13q, 17q and 20q are more frequent. Multiple 
studies have used fluorescent in situ hybridisation (FISH) to study DCIS and have found 
alteration in copy numbers of HER2, C-MYC, CCND1, COX2, CDH1, and TP53.33–36
A number of studies have sought to analyse the mutational patterns in DCIS and compare 
them with those of invasive carcinomas. Some of these studies have compared concurrent 
DCIS with invasive lesions from the same patient, while others have compared ‘pure’ DCIS 
lesions with DCIS associated with invasive carcinoma from different patients or a 
combination of the two.37 The pattern of mutations in DCIS appears to be identical to that in 
invasive carcinomas with high frequency mutations in PI3K and p53.38–40 These studies 
have also noted a significant intratumoural heterogeneity in DCIS. An important study in 
this area was undertaken by Navin and colleagues wherein single cells from concurrent 
DCIS and IDC were analysed for their mutation status.41 They developed and applied 
topographical single cell sequencing (TSCS) to analyse the genomic copy number profiles of 
1,293 cells from 10 patients. The study documented nearly identical mutational patterns in 
these lesions, suggesting the development of invasion does not need additional mutations. It 
also suggested a multi-clonal invasion model in which one or more clones assist each other 
in order to escape the ducts and establish the invasive carcinomas. Epigenetic events in 
tumour cells might be critical drivers for the progression. A number of studies have analysed 
DNA methylation, non-coding RNA, histone modification and chromatin remodelling 
patterns in DCIS and associated these with progression (reviewed by DeVaux and 
Herschkowitz42). Alterations in the character and function of the tumour microenvironment 
could play a major role.43–45 There are no data currently available to justify routine genomic 
analysis of DCIS.
RNA expression analysis—RNA expression analysis compares DCIS with concurrent 
invasive lesions or pure DCIS with DCIS associated with invasive cancers.46–50 The patterns 
of expression have been found to be fairly similar. Hannemann et al. analysed a series of 40 
in situ lesions and compared them with 40 invasive carcinomas using an 18K expression 
array.51 They identified 300 differentially expressed genes and developed a 43-gene 
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classifier that could distinguish low grade DCIS from high grade and a 35-gene classifier to 
distinguish DCIS from invasive carcinoma. Interestingly, many of the genes identified in the 
classifier belong to the signal transduction and cell growth and maintenance pathways. 
Muggerud et al. studied a set of genes that identified a group that was most similar to 
invasive cancers.52 This group was enriched in genes related to reorganisation of the 
microenvironment. Kristensen et al., applied an integrated approach by modeling mRNA, 
copy number alterations, microRNAs, and methylation in a pathway context utilising the 
pathway recognition algorithm using data integration on genomic models (PARADIGM).53 
They found a great degree of similarity in the expression pattern of the five subtypes 
(PDGM1–5) in DCIS and invasive carcinoma with the exception of PDGM2, which was not 
identified in any of the 36 cases of (pure) DCIS. They did not find an association between 
PDGMs and grade, Ki-67 or HER2 staining. Lesurf et al.,39 integrated mRNA, miRNA and 
copy number analyses to identify features that are unique to each of the intrinsic subtypes of 
DCIS. Their analysis suggests that there are subtype specific features that determine 
likelihood of recurrence.
Multi-parametric tools including commercial assays
Nomograms: The need for predictors of likelihood of presence of invasive carcinoma or 
development of recurrence has resulted in the development of multiple nomograms. The Van 
Nuys prognostic index (VNPI) is based on patient’s age, lesion size and grade, and margin 
width.54,55 It stratifies patients into three risk groups and provides treatment guidelines to 
achieve less than 20% recurrence rate at 12 years. The limitations of this nomogram include 
lack of robust independent validation and failure to include molecular characteristics. A 
more recent modification of this nomogram incorporates Genomic Grade Index (GGI) but 
needs further validation.56 The Memorial Sloan Kettering (MSKCC) nomogram57 is based 
on age, family history, clinical features at initial presentation, nuclear grade, presence of 
necrosis, margins, number of excisions, type of surgery, radiation and endocrine therapy. It is 
widely used and validated in multiple independent studies. However, there are some 
concerns regarding under-estimation of heterogeneity in DCIS.58 More recently, the Mayo 
group has described a nomogram to predict upstaging of DCIS to invasive carcinoma.59
Oncotype Dx DCIS score: The Eastern Co-operative Oncology Group (ECOG) had 
undertaken a registration (non-randomised) clinical trial of DCIS wherein patients were 
offered complete surgical excision (with centrally confirmed clean margins) but no radiation 
therapy.60 Patients were enrolled onto one of two study cohorts (not randomly assigned): 
cohort 1, low or intermediate grade DCIS, tumour size ≤2.5 cm (n=561); or cohort 2, high-
grade DCIS, tumour size ≤1 cm (n=104). Blocks were obtained from a subset of patients 
(n=327) for Oncotype DX recurrence score and DCIS Score. The 21-gene recurrence score 
was not associated with likelihood of ipsilateral breast event (IBE). In contrast, DCIS score 
was prognostic for identifying both the likelihood of recurrent DCIS and/or development of 
invasive disease.24 These findings have been independently confirmed by Rakovitch’s group 
in a large study from Toronto.23 One of the limitations of these studies is that the vast 
majority (>95%) of the DCIS cases were ER positive; the relevance of the signature in ER 
negative DCIS has not been established.
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DCISionRT (PreludeDx): DCISionRT from PreludeDx analyses the expression of a set of 
markers (HER2, PR, Ki-67, COX2, p16/INK4A, FOXA1 and SIAH2) to identify benefit of 
radiotherapy. It has been validated in multiple independent cohorts from the USA (Kaiser 
Permanente and UMass), Sweden (Uppsala) and Australia (Melbourne).30 The test has been 
recently used in cohort of 526 patients with DCIS treated with breast conserving surgery 
with or without radiotherapy (RT). In this cohort, it was prognostic for risk and predicted RT 
benefit.29
MANAGEMENT ISSUES AND NEWER CLINICAL TRIALS
The management of DCIS has evolved considerably within last few decades. Until the 
mid-1980s, DCIS was routinely treated with mastectomy.61 The National Surgical Adjuvant 
Breast Project (NSABP) B06 clinical trial compared the role of lumpectomy with 
mastectomy in the treatment of breast cancer.62 Retrospective analysis of these cases showed 
that a small percentage of the 2072 patients (n=76) had (mostly palpable) DCIS. Twenty-one 
of these patients had been treated with lumpectomy; of these nine patients (43%) developed 
recurrence. The recurrence rate for patients with lumpectomy plus radiation (XRT) was 7%, 
while that for patients undergoing mastectomy was 0%. The value of addition of radiation to 
lumpectomy was further confirmed in the NSABP B17 clinical trial in which 81% of the 
patients had non-palpable DCIS.61,63 A dramatic decrease in rates of recurrent DCIS (13.4% 
to 8.2%) and development of invasive disease (13.4% to 3.2%) was observed in patients 
receiving radiation. The compilation of results from multiple clinical trials by the early 
breast cancer trialists groups has documented a 50% reduction in IBEs after addition of 
radiation to lumpectomy.64 Further reduction in recurrence rates also has been observed 
following the addition of tamoxifen to surgery and radiation (L+ RT+ Tam), making this the 
standard of care for treatment of DCIS. In a relatively recent series, Palazzo’s group studied 
the outcomes of 141 patients treated with surgery only. Despite negative margins, 60 
recurrences (42.5%) were observed after a median follow-up of 122 months.65 In contrast, 
Tadros et al. reported that for patients with close margins (<2 mm), the addition of radiation 
was associated with dramatic reduction in recurrence rates at 10 years (30.9% vs 4.8%).66 
There was marginal benefit in adding radiation therapy to patients with greater than 2 mm 
margins (5.4% and 3.3%, respectively) in this study.
There is a major concern that the standard of care therapy for DCIS (L+ RT+ Tam) might be 
unnecessarily aggressive for patients with small screen detected DCIS. This has resulted in a 
number of clinical trials that are addressing the question of reduction of therapy for these 
patients. The Comparison of Operative to Monitoring and Endocrine Therapy (COMET) 
trial enrols patients with non-comedo DCIS for medical (non-surgical) management.67 
Similarly, LORIS (Low RIsk DCIS) and LORD (Low Risk DCIS) trials are being conducted 
around the world to address the issues.68,69 Trial enrolment is based on the subjective 
assessment of grade and absence of comedo necrosis. A recent study by Schnitt’s group 
documented the poor correlation amongst pathologists in determining ‘comedo necrosis’.70 
In this vein, it is important to remember that a significant number of DCIS lesions, 
approximately 25%, are upstaged to invasive carcinoma on excision;71–75 these might be 
missed in these trials. Based on archival data, it has been estimated that approximately 20% 
of patients enrolled in the LORIS trial will have invasive cancer.69 However, a recent 
Badve and Gökmen-Polar Page 7













analysis found the upstaging rates to invasive disease were only 6% (5/81), 7% (5/74), and 
10% (1/10) for the COMET, LORIS, and LORD trials, respectively.67 It is critical that all 
conservatively managed patients should be closely monitored.
CONCLUSION AND FUTURE CHALLENGES
There has been steady, albeit slow, progress in understanding the biology of DCIS. There are 
multiple lines of evidence to document that DCIS is not a single entity but a collection of 
biologically heterogeneous lesions. Biologically, the cells in these lesions seem to have 
acquired all the necessary mutations and are poised to invade. However, the critical event 
necessary for invasion is not yet identified but could be an epigenetic event involving 
tumour-stromal interactions.
Although histology, tumour markers such as ER and HER2, and stromal markers such as 
TILs, provide some clues regarding the likelihood of recurrence, our knowledge regarding 
the mechanisms associated with progression of DCIS to invasive cancer are still in their 
infancy. There is a critical need to understand intra-lesional and inter-lesional heterogeneity 
and their impact on likelihood of recurrence/progression. There is a clear and pressing need 
for development of well-annotated cohorts with treatment information and follow-up data to 
understand the molecular basis of recurrence and progression. This will require a 
collaborative multi-centre, multi-disciplinary approach, such as the Cancer Research UK 
Grand Challenge program. It will also be critical to perform integrative analysis (histology, 
mutations, copy number, mRNA, and protein levels) to predict likelihood of progression and 
impact of endocrine/radiotherapy. Ultimately, it might become necessary to have large multi-
centre trials based on biomarkers of recurrence to convince the breast community regarding 
the utility of these predictive tools.
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Focal infiltration by immune cells in ductal carcinoma in situ (DCIS) (20× objective using a 
Nikon DP27 camera using CellSens software).
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(A–D) Heterogeneity in the morphological patterns of ductal carcinoma in situ (DCIS). 
Images are taken from a needle biopsy of a single patient with DCIS (same patient as Fig. 1; 
20× objective using a Nikon DP27 camera using CellSens software). Note the range of 
architectural patterns ranging from solid to cribriform as well as the variable amounts of 
necrosis in the ducts.
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